Today's Hours: 8:00am - 10:00pm


Filter Applied Clear All

Did You Mean:

Search Results

  • Book
    Mikhail V. Kiselevskiy, Amir G. Abdulaev, Mikhail M. Davydov, editors.
    Summary: This book covers different aspects of the rare neoplasms - malignant mesothelioma and pseudomyxoma peritonei. The monograph includes up-to-date information on etiology, pathogenesis and diagnostics of malignant mesothelioma and pseudomyxoma peritonei, as well as detailed description of surgical and combined treatment of patients with these diseases. The book comprises a large illustrative material presented by schemes and original micrographs that represent pathological and immunohistochemical specific features of these malignancies, demonstrate the stages of surgical operations and hyperthermic intraperitoneal chemotherapy, and show the results of experimental studies. The book includes validated discussion on etiology and pathogenesis of malignant mesothelioma and pseudomyxoma peritonei, differential diagnosis and treatment of these diseases. The scope is really extensive and involves, for instance, a description of the technique of cytoreductive surgeries and regimens of intraperitoneal hyperthermic chemoperfusion, whereas a particular section discusses experimental ground for optimal regimens of hyperthermia, local chemotherapy and adoptive immunotherapy by cytokine induced killers. The final section presents the most recent data about perspective approaches for immunotherapy of malignant mesothelioma and pseudomyxoma peritonei with cell based technologies and target drugs including inhibitors of immune checkpoints. The co-authors of the book are leading specialists in this area, surgeons and scientists who present the results of their research along with the analysis of the state-of-the-art of this problem. The book is designed for a wide audience of students and professors of medical universities and schools, specialists of research and diagnostic centers, practical oncologists and immunologists, as well as doctors of different medical areas. .

    Intro; Foreword; Contents; Contributors;
    Chapter 1: Mesothelioma and Pseudomyxoma peritonei: Incidence, Etiology, Diagnosis; 1.1 Pseudomyxoma peritonei; 1.1.1 Immuno-pathologic and Molecular-Genetic Diagnosis of Pseudomyxoma peritonei; 1.2 Malignant Peritoneal Mesothelioma; 1.2.1 Etiology and Pathogenesis of Peritoneal Mesothelioma; 1.2.2 Immuno-pathologic and Molecular-Genetic Diagnostics of Peritoneal Mesothelioma; 1.2.3 Differential Diagnosis of Peritoneal Mesothelioma by Molecular Methods; 1.3 Conclusion; References
    Chapter 2: Pathology of Selected Primary and Metastatic Tumors of Peritoneum2.1 Primary Mesothelial Lesions of the Peritoneum; 2.1.1 Pathobiology of Mesothelial Tumor and Tumor-Like Lesions of the Peritoneum; Adenomatoid Tumor; Well-Differentiated Papillary Mesothelioma; Diffuse Malignant Mesothelioma; Prognostic Parameters of Malignant Peritoneal Mesothelioma.; 2.2 Non-neoplastic Mesothelial Lesions; 2.2.1 Reactive Mesothelial Hyperplasia; 2.2.2 Multicystic Mesothelioma; 2.3 Selected Metastatic Peritoneal Lesions; 2.3.1 Peritoneal Pseudomyxoma; References
    Chapter 3: Up to Date Approaches to Treatment of Patients with Pseudomyxoma Peritonei and Peritoneal Mesothelioma3.1 Patient Examination; 3.1.1 Assessment of Functional Status; 3.2 Intraperitoneal Chemotherapy; 3.3 Cytoreductive Surgery; 3.3.1 Complications of Surgical Treatment; 3.4 Intraperitoneal Chemotherapy; 3.4.1 Parameters of HIPEC; 3.4.2 Chemotherapy Drugs for Intraperitoneal Infusion; 3.5 Combined Treatment of Patients with Pseudomixoma Peritonei; 3.6 Combined Treatment of Patients with Peritoneal Mesothelioma; 3.7 Prognostic Factors for Peritoneal Pseudomyxoma and Mesothelioma 3.8 Complications of Combined Treatment - Cytoreductive Surgery, Intraperitoneal Chemotherapy3.9 Conclusion; References;
    Chapter 4: Standardizing of Mesothelioma and Pseudomyxoma Care; 4.1 Introduction; 4.1.1 Histological Aspects; 4.1.2 Patient Selection; 4.1.3 Perioperative Oncological Management; 4.1.4 Technical Aspects; 4.1.5 Right Colectomy During CRS-HIPEC Procedures; 4.1.6 Perforated Mucocele: What to Do?; 4.1.7 Mesothelioma Peritoneal; General Aspects; Treatment; 4.1.8 Intraperitoneal Chemotherapy Schedules for DMPM and PMP; 4.2 Conclusions; References
    Chapter 5: Experimental Basis for Optimal Regimnes of Hyperthermic Peritoneal Chemotherapy5.1 Impact of Hyperthermia on Physiological Activity of Tumor and Non-Transformed Cells In Vitro; 5.2 Impact of Hyperthermia on Proliferative Activity of Tumor Cells In Vivo; 5.3 Effects of Anticancer Drugs and Their Combination with Hyperthermia on the Viability of Tumor Cells In Vitro; 5.4 Effect of Hyperthermia on the Effectors of Antitumor Immunity; 5.5 Conclusion; References;
    Chapter 6: Immunotherapy of Malignant Peritoneal Mesothelioma and Pseudomyxoma Peritonei; 6.1 Adoptive Immunotherapy
    Digital Access Springer 2019